In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.
Read More
Future of BCMA-Targeted Therapies in Multiple Myeloma
Read More
Bispecific Antibodies for Multiple Myeloma
Read More
Differentiating among CAR T Products for Multiple Myeloma
Read More
Development of CAR T Cells in Multiple Myeloma
Read More
Using Antibody-Drug Conjugates in Multiple Myeloma
Read More
BCMA-Targeted Therapies in Multiple Myeloma
Read More
BELLINI Trial; Venetoclax-Vd in Multiple Myeloma
Read More
BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma
Read More
Lenalidomide-Refractory Multiple Myeloma
Read More
Daratumumab With Carfilzomib in Frontline Multiple Myeloma
Read More
Management of Relapsed/Refractory Multiple Myeloma
Read More
Maintenance Therapy Approaches in Multiple Myeloma
Read More
MRD Monitoring in Multiple Myeloma
Read More
The Role of Transplant in Multiple Myeloma
Read More
Treating Transplant-Eligible and -Ineligible MM
Read More
Transplant-Ineligible Multiple Myeloma
Read More
Tolerability of Triplet Therapy in Multiple Myeloma
Read More
Frontline Triplet Therapies in Multiple Myeloma
Read More
Dr. Raje Compares Data for Triplet Regimens in Myeloma
April 18th 2019Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses data for the standard triplet regimens in the treatment of patients with relapsed/refractory myeloma.
Read More
Dr. Raje on Treatment Approaches for Relapsed/Refractory Myeloma
April 8th 2019Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses treatment approaches for patients with relapsed/refractory multiple myeloma.
Read More